Information Provided By: 
Fly News Breaks for September 19, 2017
MDRX
Sep 19, 2017 | 07:08 EDT
RBC Capital analyst George Hill started coverage of Allscripts with a $17 price target and an Outperform rating. He is upbeat on Allscripts as he says that the shares are attractive due to the company's "core business execution, positioning for next generation HCIT solutions, accretion from the EIS acquisition, and valuation." He calls the company "an industry leader in Population Health Management and in revenue cycle management."
News For MDRX From the Last 2 Days
There are no results for your query MDRX
